C87436 Activators encompass a diverse array of chemical compounds that indirectly influence the functional activity of C87436 through specific intracellular signaling pathways. Forskolin, by raising intracellular cAMP levels, indirectly heightens the activity of C87436 by activating PKA which phosphorylates substrates within the same signaling cascade as C87436. Similarly, PMA, a DAG analog, activates PKC, which is known to phosphorylate proteins that interact with or regulate C87436, leading to an enhancement of its functionality. Ionomycin and A23187, both calcium ionophores, increase the intracellular calcium concentration, subsequently activating calcium-dependent pathways that C87436 is a part of and thus indirectly enhancing its activity. Compounds like Epigallocatechin gallate and Zaprinast, through kinase inhibition and elevation of cGMP levels respectively, lead to the activation of pathways or removal of inhibitory phosphorylations that can result in the elevated activity of C87436.
Moreover, the inhibition of signal transduction components by LY294002 (PI3K inhibitor), SB203580 (p38 MAPK inhibitor), U0126 (MEK1/2 inhibitor), and Isoquinoline sulfonamide (PKA inhibitor) can cause a shift in cellular signaling dynamicsfavorable to the pathways involving C87436, thereby indirectly augmenting its activity. Through the inhibition of PI3K, LY294002 can modulate the activity of downstream molecules like Akt, which may intersect with the pathways C87436 is involved in, leading to its enhanced function. SB203580 and U0126, by inhibiting p38 MAPK and MEK1/2 respectively, change the balance of cellular signaling to promote the activation of C87436. Additionally, Sildenafil and Zaprinast, both PDE5 inhibitors, increase cGMP levels, which activate PKG and can phosphorylate substrates in signaling cascades that include C87436, potentially enhancing its activity. Bisindolylmaleimide I, although a PKC inhibitor, can refine signaling by selectively inhibiting specific PKC isoforms, resulting in a net increase in C87436 activity by modifying the protein's signaling environment.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin activates adenylate cyclase, increasing cAMP levels in cells. Elevated cAMP activates PKA, which can phosphorylate specific substrates that lead to enhanced activity of C87436 by promoting signaling events it is involved in. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $42.00 $72.00 $124.00 $238.00 $520.00 $1234.00 | 11 | |
EGCG is a known inhibitor of certain kinases. By inhibiting these kinases, it can remove inhibitory phosphorylation events, thus indirectly increasing the activity of C87436 involved in those pathways. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $76.00 $265.00 | 80 | |
Ionomycin is a calcium ionophore that increases intracellular calcium levels. Elevated calcium can activate signaling pathways that C87436 is part of, leading to its increased functional activity. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
PMA is a diacylglycerol (DAG) analog that activates protein kinase C (PKC). Activated PKC can phosphorylate substrates that may interact with or modulate C87436 activity, thus enhancing its function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor, which can lead to altered activity of downstream signaling molecules such as Akt. This alteration can enhance the activity of C87436 by modulating the signaling pathways it participates in. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor that can shift signaling dynamics in favor of pathways that C87436 is involved in, thereby enhancing its functional activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK1/2 that can lead to decreased ERK activation. This decrease can indirectly enhance C87436 activity by modulating signaling pathways in which C87436 is a participant. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $54.00 $128.00 $199.00 $311.00 | 23 | |
A23187 is a calcium ionophore that increases intracellular calcium, similar to Ionomycin. This increase can potentiate the activity of C87436 by activating calcium-dependent signaling pathways that it is involved in. | ||||||
H-89 dihydrochloride | 130964-39-5 | sc-3537 sc-3537A | 1 mg 10 mg | $92.00 $182.00 | 71 | |
H-89 is a potent inhibitor of PKA. By inhibiting PKA, it can prevent inhibitory phosphorylation events, resulting in the activation of signaling pathways involving C87436 and enhancing its activity. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $103.00 $245.00 | 8 | |
Zaprinast inhibits PDE5 similarly to Sildenafil, leading to increased cGMP levels. This can activate PKG-related pathways and enhance the activity of C87436 by influencing signaling events it is involved in. |